Ann: Executive Leadership changes - Dr John Friend appointed CEO, page-26

I think the company has done well with 2 good potential drug candidates. Whether the board, JG or a little bit of both. Not so good on the capital raises and the timing as others have also noted. With data in the hands of independent reviews/studies the CEO has little influence here. It might be good from this perspective if costs can be reduced right now and you just need a capable person in charge ant lower cost and let the data when it comes out speak for itself. The data will influence the stock price. So far today it has been a positive reaction but it is very early. Next few days will tell.